scholarly journals Vitamin D in active systemic lupus erythematosus and lupus nephritis: a forgotten player

2020 ◽  
Vol 32 (1) ◽  
Author(s):  
Marwa K. Khairallah ◽  
Yasmine S. Makarem ◽  
Marwa A. Dahpy
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Serum Level ◽  
Lupus Nephritis ◽  
Negative Correlation ◽  
Lupus Erythematosus ◽  
Significant Negative Correlation ◽  
Systemic Lupus ◽  
Malar Rash ◽  
The Relationship

Abstract Background Systemic lupus erythematosus (SLE) is an autoimmune disorder associated with immunological abnormalities (Aringer et al., Arthritis Rheumatol 71:1400-1412, 2019). Vitamin D (VD) has an important role in SLE pathogenesis, as it controls cell cycle progression besides its anti-proliferative effects (Liu et al., J Cell Commun Signal 71, 2019). Determining the relationship between VD with SLE activity and lupus nephritis (LN) can establish a new role for VD in SLE management (Liu et al., J Cell Commun Signal 71, 2019). In our study, we aimed to assess the relationship between levels of VD in patients with SLE activity and with LN and to verify the relationship between VD levels with clinical and laboratory parameters in those patients, in order to assess the validity of adding serum VD level in the routine follow-up as a marker that may lead to earlier diagnosis of SLE activity and LN in adult SLE patients. Results Serum VD was significantly lower in SLE patients (3.38 ± 2.55 ng/ml) versus healthy controls (5.36 ± 2.88 ng/ml) (P < 0.002). Interestingly, serum VD was significantly lower in patient with active SLE according to SLEDAI (3.00 ± 2.27 ng/ml) versus those with inactive SLE (5.10 ± 3.19 ng/ml) (P < 0.02). Significant negative correlation was found between serum level of VD and each of mucocutaneous, malar rash, and renal manifestations. Significant negative correlation was also noticed among SLEDAI (P value = 0.01) and renal SLEDAI scores (P value = 0.021) with serum level of VD. Conclusion Low levels of VD were found to be frequent in SLE patients especially during phases of SLE activity and nephritis. Potent markers of low serum VD level in SLE patients were found to be mucocutaneous, malar rash, and LN. Our results support that VD levels could act as independent risk factors for activity and LN in SLE patients; moreover, treatment with VD supplementation could decrease the incidence of activity and nephritis in SLE patients.

scholarly journals P52 The relationship of vitamin D levels with disease activity in systemic lupus erythematosus

2020 ◽  
Author(s):  
Lambros Athanassiou ◽  
Ifigenia Kostoglou ◽  
Pavlos Tsakiridis ◽  
Aikaterini Tzanavari ◽  
Eirini Devetzi ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Vitamin D Levels ◽  
Relationship Of ◽  
The Relationship

scholarly journals The Relationship Between Serum Vitamin D Level and Systemic Lupus Erythematosus Activity

2020 ◽  
Vol 7 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Batool Zamani ◽  
Hossein Akbari ◽  
Mehrdad Mahdian ◽  
Ehsan Dadgostar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Lupus Erythematosus ◽  
Healthy Subjects ◽  
Linear Regression Analysis ◽  
Serum Vitamin ◽  
Control Group ◽  
Systemic Lupus ◽  
25 Hydroxy Vitamin D ◽  
The Relationship

Background and aims: : Systemic lupus erythematosus (SLE) is an autoimmune disease which involves various organs. Vitamin D is an essential ingredient in regulating the immune system. This study aimed to investigate the relationship between vitamin D and the severity of lupus activity. Materials and Methods: This case-control study was carried out on 38 patients with lupus on the basis of the American College of Rheumatology (ACR) criteria and 44 healthy subjects with no history of rheumatologic disease. To measure the level of 25-hydroxy vitamin D, venous blood samples (5 cc) were taken from each participant and the activity of the lupus disease was measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scale. Finally, the chi-square test, independent sample t test, one-way ANOVA, and multiple linear regression analysis were used to measure multivariate effects. The level of significance was set to be P<0.05. Results: Thirty-five lupus patients and 40 healthy subjects were females (P=0.847). Vitamin D deficiency was observed in the case (42.1%) and control (11.4%) groups. The mean value of serum vitamin D3 level was 35.3 ng/mL in the control group, as well as 24.6 ng/mL and 21.3 ng/mL in patients with mild and severe SLE, respectively (P=0.024). Conclusion: In this study, high levels of 25-hydroxy vitamin D were observed among the healthy subjects compared to patients with SLE. Eventually, the level of vitamin D significantly decreased by increasing the severity of SLE activity.

scholarly journals AB0124 NO EFFECTS OF HIGH DOSE 25OH-VITAMIN D SUPPLEMENTATION ON LUPUS NEPHRITIS IN AN ANIMAL MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1362.2-1362
Author(s):  
S. Barsotti ◽  
C. Tani ◽  
A. Kuhl ◽  
S. Pacini ◽  
S. Vagnani ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Vitamin D ◽  
Animal Model ◽  
Lupus Nephritis ◽  
Interstitial Nephritis ◽  
Lupus Erythematosus ◽  
Statistical Significance ◽  
High Dose ◽  
Systemic Lupus ◽  
Renal Histology

Background:25OH Vitamin D (25-OH-D3) is a fat-soluble steroid-derived molecule involved in the calcium homeostasis. Low levels of 25-OH-D3 are commonly found in patients with systemic lupus erythematosus (SLE) and have been correlated to higher disease activity and severity. Several recent studies have demonstrated that high dose Vitamin D may influence several aspects of the innate and adaptive immune response and some authors hypothesized that high dose 25-OH-D3 may have a role in the treatment of SLE. Despite these observations, the immunomodulatory effect of high dose 25-OH-D3in vivostill needs to be demonstrated.Objectives:The aim of our study was to identify the effect of 25-OH-D3 on proteinuria, survival and renal biopsy in New Zealand Black/White F1 mice (NZ), that develop a disease very similar to human SLE nephritis.Methods:We administered to 20 NZ mice a diet enriched with high dose 25-OH-D3 10,000 UI/Kg starting from 8 weeks of age. Mice were divided in 7 experimental groups (5 mice each). The first group was sacrificed before the start of the treatment (8 week of age), three groups were treated (treated mice – TM) with 25-OH-D3 and sacrificed at 16, 26 and 36 weeks of age. The other three groups were enrolled as controls and sacrificed at 16, 26 and 36 weeks of age respectively (untreated mice – UM). The parameters collected included: total urinary protein and kidney histology for the evaluation of lupus nephritis (LN): glomerulonephritis, interstitial nephritis and vascular lesions according to a 5 points scale to obtain a total score (ranging from 0 to 12).Results:In UM, proteinuria tended to increase over 1 mg/day at 12 weeks of age (1.7±0.43mg/day) and further increased until to reach a plateau after 28 weeks of age (10±2.0 mg/day).In TM, a significant increase in proteinuria over 1 mg/day was observed at 24 weeks, when the mean proteinuria was 1.7±1.33 which was lower than controls at the same age although without statistical significance (2.9±2.6); thereafter proteinuria started to increase also in treated mice and at week 30 was higher in TM compared with UM (10,3±8.8 vs 4.3±3.5 p=0.05). Figure 1.Kidney histology showed, in mice sacrificed before the start of the treatment no signs of LN. In mice sacrificed at 16 weeks minimal interstitial nephritis (score 1) was identified in 2 mice only in UM. At 26 weeks of age, a higher total LN score was identified in TM compared with UM (3.4±3.8 vs 0.4 ±0.9) with higher score for all three parameters analyzed. At 36 weeks of age, the TM group maintained a higher total LN score compared to UM (6.5±1.7 vs 6.0±2.6) with higher score for glomerulonephritis and interstitial nephritis.In the TM group, three mice spontaneously died at 26, 30 and 32 weeks of age, while in the UM only one mouse died at 36 weeks of age.Conclusion:Our data suggest that, in this animal model of SLE, 25-OH-D3 administration seems to delay the onset of proteinuria, although has no effect on the overall disease control. In addition, it may have a negative effect on renal histology and survival with earlier development of LN.Figure:Disclosure of Interests:None declared

scholarly journals AB0839 A STUDY OF SERUM COMPLEMENT AND SERUM CALPROTECTIN LEVEL IN SYSTEMIC LUPUS ERYTHEMATOSUS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1443.2-1443
Author(s):  
H. Goswami ◽  
S. Kakati
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Negative Correlation ◽  
Lupus Erythematosus ◽  
Tertiary Care ◽  
Significant Negative Correlation ◽  
Serum Complement ◽  
Systemic Lupus ◽  
Female Population ◽  
Calprotectin Level

Background:Serum calprotectin, also known as MRP8/14 or S100A8/A9, has gained attention in recent years as a candidate biomarker in inflammatory diseases like SLE.1 Proteins of the complement pathway (serum C3 and C4) are linked to the pathogenesis of SLE and their levels have been measured as a means to assess the disease activity.2Objectives:[1]To study the relation of serum complement and serum calprotectin levels to disease activity in SLE[2]To study the relation between serum complement and serum calprotectin level in SLEMethods:Our study was a hospital based observational study conducted in a tertiary care centre in North-East India during the period of June 2019 to May 2020. A total of 102 patients of SLE were taken up for the study. Disease activity was assessed using SLEDAI-2K scores and serum calprotectin level was measured by ELISA. Serum C3 level was assessed by Nephelometric and C4 level by Turbidimetric immunoassay. The statistical significance was fixed at 5% level of significance (p<0.05) for all analysis.Results:Our study found a predominantly female population (Female: Male ratio 24.5: 1) with majority of the patients (49.02%) in the 30-39 years age group. Higher calprotectin levels were seen in patients with higher disease activity (SLEDAI) and this relation was statistically significant (r=0.84, p<0.001). There was significant negative correlation between disease activity (SLEDAI) and serum C3 (r=-0.35, p<0.001) and serum C4 (r=-0.4, p<0.001) level. There was a significant negative correlation between complement levels and serum calprotectin levels (r=-0.53, p<0.001).Conclusion:We found a significant positive correlation between serum calprotectin level and disease activity with a significant negative correlation between complement level and disease activity in SLE patients. There was a significant negative correlation between serum complement and serum calprotectin levels. These findings suggest serum calprotectin levels could be a substantial addition in the existing diagnostic array of tools in assessing lupus disease activity.References:[1]García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: Association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagnosis Ther. 2013;17(1):49–56.[2]Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4(Suppl 3):S279-293.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document